Conclusions and treatment recommendations for the acute episode in schizophrenia

International Clinical Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages 93-100

  Gaebel, W ^a   Marder, S ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute episode; Diagnosis; Prognosis; Schizophrenia; Treatment

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SERTINDOLE;

CONFERENCE PAPER; FAMILY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SCHIZOPHRENIA;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; FAMILY; GUIDELINES; HUMANS; PROGNOSIS; REHABILITATION, VOCATIONAL; SCHIZOPHRENIA; SOCIAL SUPPORT;

EID: 0029901411     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199605002-00015     Document Type: Conference Paper

References (75)

1. American Psychiatric Association (1989) Treatment of Psychiatric disorders: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatrie Association.
2. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Awad AG (1994) Prediction research of neuroleptic treatment outcome in schizophrenia: state of the art 1978-1993. In Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods. Edited by Gaebel W, Awad AG. New York: Springer; pp 1-14.
4. Bachrach LL (1992) Case management revisited. Hosp Community Psychiatry 43:209-210.
5. Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45:79-90.
6. Barrowchough C, Tarrier N (1992) Interventions with families. In Innovations in the Psychological Management of Schizophrenia. Edited by Birch wood M, Tarrier N. Chichester: Wiley; pp 79-101.
7. Bellack AS, Mueser KT (1993) Psychosocial treatment of schizophrenia. Schizophr Bull 19:317-336.
8. Bellack AS, Morrison RL, Mueser KT (1989) Social problem solving in schizophrenia. Schizophr Bull 15:101-116.
9. Birchwood M, Macmillan F, Smith J (1992) Early intervention. In Innovations in the Psychological Management of Schizophrenia. Edited by Birchwood M, Tarrier N. Chichester: Wiley; pp 115-145.
10. Bleuler E (1911) Dementia praecox oder Gruppe der Schizophrenien. Leipzig: Deuticke.
11. Bleuler M, Huber G, Gross G, Schüttler R (1976) Der langfristige Verlauf schizophrener Psychosen. Nervenarzt 47:477-481.
12. Bondolfi G, Baumann P, Patris M, et al. (1995) A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia. In 148th Annual Meeting of the American Psychiatric Association, May, 1995, Miami, Florida. Washington, DC: American Psychiatric Association.
13. Breier A, Buchanan RW, Kirkpatrick B, et al. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20-26.
14. Brenner HD, Böker W, Müller J, Spichtig L, Wurgler S (1987) On autoprotective efforts of schizophrenics, neurotics and controls. Acta Psychiatr Scand 75:405-414.
15. Brown GW, Bone M, Dalison B, Wing JK (1966) Schizophrenia and Social Care. Oxford: Oxford University Press.
16. Chouinard G, Jones B, Remington G, et al (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 13:25-40.
17. Clarkin JF, Click ID, Haas G, et al. (1991) The effects of inpatient family intervention on treatment outcome. In Psychiatric Treatment. Advances in Outcome Research. Edited by Mirin S, Gossett JT, Grob MC. Washington, DC: American Psychiatric Press; pp 47-59.
18. Dilling H, Mombour W, Schmidt MH (1992) International Classification of Diseases, ICD-10 [in German]. Bern: Hans Huber.
19. Engel GL (1980) The clinical application of the biopsychosocial model. Am J Psychiatry 137:535-544.
20. Falloon IRH, Boyd JL, McGill CW, Razani J, Moss HB, Gilderman AM (1982) Family management in the prevention of exacerbations of schizophrenia: a controlled study. N Engl J Med 306:1437-1440.
21. Falloon IRH, Boyd JL, McGill CW, et al. (1985) Family management in the prevention of morbidity of schizophrenia: Clinical outcome of a two year longitudinal study. Arch Gen Psychiatry 42:887-896.
22. Gaebel W, Awad G (1994) Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods. New York: Springer.
23. Gaebel W, Wölwer W (1992) Facial expression and emotional face recognition in schizophrenia and depression. Eur Arch Psychiatry Clin Neurosci 242:46-52.
24. Gaebel W, Pietzker A, Ulrich G, Schley J, Müller-Oerling-Hausen B (1988) Predictors of neuroleptic treatment response in acute schizophrenia. Pharmacopsychiatry 21:384-386.
25. Häfner H, An der Heiden W (1991) Evaluating effectiveness and cost of community care for schizophrenic patients. Schizophr Bull 17:441-451.
26. Harding CM, Brooks GW, Ashikaga T, et al. (1987) The Vermont longitudinal study of persons with severe mental illness: II. Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia [abstract]. Am J Psychiatry 144:735.
27. Hermanutz M, Gestrich J (1987) Cognitive training with schizophrenics [in German]. Nervenarzt 58:91-96.
28. Hirsch SR, Bower JT, Emami J, et al. (1993) The effect of life events and medication in the aetiology of schizophrenic relapse [abstract]. Schizophr Res 9:266.
29. Hogan T, Awad G (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 13:177-183.
30. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF (1974) Drug and sociotherapy in the aftercare of schizophrenic patients: two year relapse rates. Arch Gen Psychiatry 31:603-608.
31. Hogarty GE, Anderson CM, Reiss DJ, et al. (1986) Family psychoeducation, social skills training and maintenance chemotherapy in the aftercare treatment of schizophrenia. Arch Gen Psychiatry 43:633-642.
32. Hogarty GE, Anderson CM, Reiss DJ (1987) Family psychoeducation social skills training and medication in schizophrenia. Psychopharmacol Bull 23:12-13.
33. Hogarty GE, McEvoy JP, Munetz M, et al. (1988) Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 45:797-805.
34. Janicak PG, Davis JM, Preskorn SH, Ayd FJ (1993) Principles and Practice of Psychopharmacology. Baltimore: Williams and Wilkins; pp 93-184.
35. Johnson DAW (1984) Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 45:13-21.
36. Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/benztropine. Arch Gen Psychiatry 45: 789-796.
37. Kendell RE, Brockington IF, Leff JP (1979) Prognostic implications of six alternative definitions of schizophrenia. Arch Gen Psychiatry 36:25-31.
38. Kissling W (ed) (1991) Guidelines for Relapse Prevention in Schizophrenia. Berlin: Springer.
39. Kraemar S, Sulz KHD, Schmidt R, Lassie R (1987) Kognitive Therapie bei standardversorgten schizophrenen Patienten. Nervenarzt 58:84-90.
40. Kraepelin E (1919) Dementia Praecox and Paraphrenia. Edinburgh, Churchill Livingstone. Translated by Barcley RM, Robertson GM. New York: Krieger; 1971.
41. Langsley DG, Hodes M, Grimson WR (1993) Psychosocial interventions. In Treatment of mental disorders. Edited by Sartorius N, de Girolamo G, Andrews G, German GA, Eisenberg L. Washington, DC: American Psychiatric Press; pp 253-288.
42. Leff JP, Vaughn C (1981) The role of maintenance therapy and relatives' expressed emotion in relapse of schizophrenia: a two-year follow-up. Br J Psychiatry 139:102-104.
43. Leff JP, Kuipers L, Berkowitz R, Eberlein-Vries R, Sturgeon D (1982) A controlled study of social intervention in families of schizophrenic patients. Br J Psychiatry 141:121-134.
44. Leff JP, Kuipers L, Berkowitz R, et al. (1985) A controlled trial of social intervention in the families of schizophrenic patients: two-year follow-up. Br J Psychiatry 146:594-600.
45. Lieberman JA (1993) Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 54 (suppl 3):13-17.
46. Liberman RP, Falloon IRH, Aitchison RA (1984a) Multiple family therapy for schizophrenics: a behavioural approach [abstract]. Psychosoc Rehabil J 4:60.
47. Liberman RP, Falloon IRH, Wallace CJ (1984b) Drug-psychosocial interactions in the treatment of schizophrenia. In The Chronically Mentally III: Research and Services. Edited by Mirabi M. New York: SP Medical and Scientific Books.
48. Liberman RP, Lillie F, Falloon IRH, Harpin RE, Hutchinson W, Stoute B (1984c) Social skills training with relapsing schizophrenics: an experimental analysis [abstract]. Behav Modif 8:155.
49. Liberman RP, Mueser KT, Wallace CJ, Jacobs HJE, Eckman T, Massel HK (1985) Training skills in the psychiatrically disabled: learning coping and competence. Schizophrenia Bull 12:631-647.
50. Linden M (1993) Massnahmen zur Föderung der Patienten-Compliance. In Therapie psychiatrischer Erkrankungen. Edited by Möller HJ. Stuttgart: Enke; pp 104-113.
51. Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DJ, Geisler SH, Szymanski SR (1992) Duration of psychosis and outcome in first-episode-schizophrenia. Am J Psychiatry 149: 1183-1188.
52. McGlashan TH (1991) Selective review of recent North American long-term follow-up studies of schizophrenia. In Psychiatric Treatment: Advances in Outcome Research. Edited by Mirin SM, Gossett JT, Grob MC. Washington DC: American Psychiatric Press; pp 61-105.
53. McGlashan TH (1994) Psychosocial treatment of schizophrenia. The potential of relationships. In Schizophrenia. From Mind to Molecule. Edited by Andreasen NC. Washington, DC: American Psychiatric Press; pp 189-215.
54. May PRA, Goldberg SC (1978) Prediction of schizophrenic patients' response to pharmacotherapy. In Psychopharmacology: A Generation of Progress. Edited by Lipton MA, Dimascio A, Killam KF. New York: Raven Press; pp 1139-1153.
55. May PRA, Van Putten T, Yale C, et al. (1976) Predicting individual responses to drug treatment in schizophrenia: a test dose model. J Nerv Ment Dis 162:177-183.
56. Marder SR, Meibach RC (1994) Riperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835.
57. Naber D, Walther A, Kircher T, Hayek D, Holzbach R (1994) Subjective effects of neuroleptics predict compliance. In Prediction of Neuroleptic Treatment Outcome in Schizophrenia: Concepts and Methods. Edited by Gaebel W, Awad AG. New York: Springer; pp 85-98.
58. Nuechterlein KH (1987) Vulnerability models for schizophrenia: state of the art. In Search For the Causes of Schizophrenia. Edited by Hafner H, Janzarik W, Gattaz W. Heidelberg: Springer; pp 297-316.
59. Pietzcker A, Gaebel W (1993) Prediction of 'natural' course, relapse, and prophylactic response in schizophrenic patients. Pharmacopsychiatry 16:206-211.
60. Roder V (1988) Untersuchungen zur Effektivität kognitiver Therapieinterventionen mit schizophrenen Patienten. Bern: Inaugural dissertation, University of Bern.
61. Shapiro AK (1969) Iatroplacebogenics. Int Pharmacopsychiatry 2:215-248.
62. Siris SG (1993) Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications [review] Br J Psychiatry 163 (suppl 22):66-78.
63. Tarder N, Barrowclough C, Vaughn C, et al. (1988a) The community management of schizophrenia: a controlled trial of behavioural intervention with families to reduce relapse. Br J Psychiatry 153:532-542.
64. Tarrier N, Barrowclough, D'Ambrosio P (1988b) A training programme in psychosocial intervention with families with a schizophrenic member. Behav Psychother 27:2-4.
65. Tarrier N, Barrowclough C, Vaughn C, et al (1989) The community management of schizophrenia: a two years follow-up of a behavioural intervention with families. Br J Psychiatry 154:625-628.
66. Thurm-mussgay I, Häfner H (1990) Bewältigung der Krankheit Schizophrenie und ihrer Folgen. In Therapy of Schizophrenia [inGerman]. Edited by Olbrich R. Stuttgart: Kohlhammer; pp 151-178.
67. Tuma H, May PRA, Yale C, et al. (1978) Therapist characteristics and the outcome of treatment in schizophrenia. Arch Gen Psychiatry 35:81-85.
68. Vaccaro JV, Roberts L (1992) Teaching social and coping skills. In Innovations in the psychological management of schizophrenia. Edited by Birchwood M, Tarrier N. Chichester: Wiley; pp 103-114.
69. Van Putten T, May PRA (1978) Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 35:477-480.
70. Vaughn CE, Leff JP (1976) The influence of family and social factors on the course of psychiatric illness. Br J Psychiatry 129:125-137.
71. Vaughn CE, Snyder KS, Freeman W, et al. (1982) Family factors in schizophrenic relapse: a replication. Schizophr Bull 8:425-426.
72. Wallace CJ, Nelson CJ, Liberman RP, et al. (1980) A review and critique of social skills training with schizophrenic patients. Schizophr Bull 6:42-63.
73. Wing JK (1978) The social context of schizophrenia. Am J Psychiatry 135:1333-1339.
74. World Health Organization (1979) Schizophrenia. An International Follow-up Study. Chichester: Wiley.
75. Wyatt RJ (1991) Neuroleptics and the natural course of schizophrenia. Schizophr Bull 17:325-351.